DaVita stock has delivered a 78.0% return over the past three years, yet the latest valuation checks still suggest the shares lean cheap rather than fully priced in.

• Over three years DaVita has returned 78.0%, which puts more focus on whether the current valuation leaves enough room for further upside.
• Future cash generation from its dialysis network can support the current share price, but ongoing cost pressures and reimbursement uncertainty may limit how much investors are willing to pay for that cash flow.
• DaVita screens as undervalued on most measures, with the broader checks indicating it is attractively priced in 5 out of 6 valuation tests.

The issue now is whether DaVita's share price around US$179 already reflects this strong recent run or still offers a margin of safety on the current fundamentals.

Is DaVita a Bargain on Earnings?

The P/E ratio suits DaVita because earnings remain a key anchor for how investors look at a mature healthcare service business. On this metric, DaVita trades on a P/E of about 13.9x, which is well below the Healthcare industry average of roughly 24.9x and also under the peer group average of about 41.9x. That places the stock at a clear discount based purely on what investors are currently paying for each dollar of earnings.

A more tailored fair P/E, which considers DaVita’s characteristics such as margins, scale and sector risk, sits near 25.8x. Compared with the current 13.9x multiple, that is a wide gap and indicates the market is pricing DaVita’s earnings more cautiously than this framework implies. If earnings hold around present levels, that kind of discount can matter a lot for long term holders who focus on valuation entry points.

On the P/E multiple, DaVita stock appears undervalued relative to both its fair ratio and the wider Healthcare sector.

The DaVita Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for DaVita pick up where the valuation puzzle leaves off and spell out which assumptions about DaVita's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Each narrative links a fair value to a clear story about the company's possible catalysts and risks, so you can track over time which version of events appears to be unfolding.

Community views on DaVita sit far apart, with one camp seeing clear value and the other flagging limited upside from here.

Bull case: 14% undervalued

"Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes..."

Bear case: 9% overvalued

"Persistent pressure on treatment volumes, including the recent 1.5% year over year decline in U.S. treatments per day and elevated missed treatment rates, could indicate a weaker long term growth base..."

Do you think there's more to the story for DaVita? Head over to our Community to see what others are saying!

The Bottom Line

DaVita still screens as undervalued on market multiples, even after a strong three year return profile. The key question is whether that discount reflects genuine mispricing or simply the market’s caution around reimbursement risk and ongoing cost pressures.

For many investors, the crux now is whether DaVita can sustain earnings quality and cash generation in the face of these pressures. If that holds, the current multiple could look conservative. If it does not, the apparent value may prove to be a value trap rather than an opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.